Delving into the Latest Updates on YKYY032 with Synapse

Overview

Basic Info

Drug Type

siRNA

Synonyms-

Target

Lp(a)

Action

inhibitors

Mechanism

lipoprotein(a) inhibitors

Therapeutic Areas

Endocrinology and Metabolic DiseaseCardiovascular Diseases

Active Indication

Lipoprotein (a) hyperlipoproteinemiaAtherosclerosis

Inactive Indication-

Originator Organization

Yuekang Pharmaceutical Group Co., Ltd.

Active Organization

Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd.

Hangzhou Tianlong Pharmaceutical Co., Ltd.

Yuekang Pharmaceutical Group Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Boost your research with our RNA technology data.

login

or

view full example data

Boost your research with our RNA technology data.

主要目的评价Lp(a)升高参与者单次皮下注射YKYY032注射液后的安全性和耐受性；次要目的评价Lp(a)升高参与者单次皮下注射YKYY032注射液后的药代动力学（Pharmacokinetics，PK）特征；评价Lp(a)升高参与者单次皮下注射YKYY032注射液后的药效学（Pharmacodynamics，PD）特征；探索性目的评价Lp(a)升高参与者单次皮下注射YKYY032注射液后的免疫原性；评价单次皮下注射YKYY032注射液后对QTc间期的影响；评价Lp(a)升高参与者单次皮下注射YKYY032注射液后对其他探索性生物标志物的影响。

[Translation]

Primary Objectives: Evaluate the safety and tolerability of a single subcutaneous injection of YKYY032 in participants with elevated Lp(a). Secondary Objectives: Evaluate the pharmacokinetic (PK) characteristics of a single subcutaneous injection of YKYY032 in participants with elevated Lp(a); Evaluate the pharmacodynamic (PD) characteristics of a single subcutaneous injection of YKYY032 in participants with elevated Lp(a). Exploratory Objectives: Evaluate the immunogenicity of a single subcutaneous injection of YKYY032 in participants with elevated Lp(a); Evaluate the effect of a single subcutaneous injection of YKYY032 on the QTc interval; Evaluate the effect of a single subcutaneous injection of YKYY032 on other exploratory biomarkers in participants with elevated Lp(a).

Start Date-

Sponsor / Collaborator

Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd.

[+1]

100 Clinical Results associated with YKYY032

Login to view more data

100 Translational Medicine associated with YKYY032

Login to view more data

100 Patents (Medical) associated with YKYY032

Login to view more data

100 Deals associated with YKYY032

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Lipoprotein (a) hyperlipoproteinemia	Phase 1	China	Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd.	22 Dec 2025
Lipoprotein (a) hyperlipoproteinemia	Phase 1	China	Hangzhou Tianlong Pharmaceutical Co., Ltd.	22 Dec 2025
Atherosclerosis	Preclinical	China	Yuekang Pharmaceutical Group Co., Ltd.	15 Mar 2025